Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Saved in:
| Title: | Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. |
|---|---|
| Authors: | Li M; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Sack JS; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Rahma OE; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hodi FS; Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zucker SD; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Grover S; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts. |
| Source: | Cancer [Cancer] 2020 Dec 01; Vol. 126 (23), pp. 5088-5097. Date of Electronic Publication: 2020 Sep 05. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.33165 |
